Cardiff Oncology

CRDF69

Penny Stock

$2.46arrow_drop_down3.14%-$0.08

Penny Stock

CRDF69

$2.46

arrow_drop_down3.14%-$0.08

Penny Stock

Performance History

Key Stats
Open	$2.62
Prev. Close	$2.54
EPS	-0.92
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$118.23M
PE Ratio	-

	LOW	HIGH
Day Range	2.45	2.65
52 Week Range	0.94	6.42

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-0.92

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About Cardiff Oncology (CRDF)

Cardiff Oncology, Inc. (CRDF) is a biotechnology company focused on the development of novel cancer therapies. The company is dedicated to improving the lives of patients with cancer through the discovery and development of innovative treatments. With a strong pipeline of potential therapies, Cardiff Oncology is well positioned to make a significant impact in the field of oncology.

One of the key factors that sets Cardiff Oncology apart from its peers is its commitment to smart analysis. The company utilizes advanced data analytics and artificial intelligence to gain insights into the complex biological mechanisms underlying cancer. By leveraging these cutting-edge technologies, Cardiff Oncology is able to identify promising drug targets and develop targeted therapies with a higher likelihood of success.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Mark Erlander Ph.D.
Headquarters: San Diego
Employees: 25
Exchange: NASDAQ

Keep an eye on Cardiff Oncology

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is Cardiff Oncology's (CRDF) price per share?

The current price per share for Cardiff Oncology (CRDF) is $2.46. The stock has seen a price change of -$0.08 recently, indicating a -3.15% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for Cardiff Oncology (CRDF)?

For Cardiff Oncology (CRDF), the 52-week high is $6.42, which is 160.98% from the current price. The 52-week low is $0.94, the current price is 161.7% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is Cardiff Oncology (CRDF) a growth stock?

Cardiff Oncology (CRDF) has shown an average price growth of 0.41% over the past three years. It has received a score of 87 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying Cardiff Oncology as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is Cardiff Oncology (CRDF) stock price performance year to date (YTD)?

As of the latest data, Cardiff Oncology (CRDF) has a year-to-date price change of 60.78%. Over the past month, the stock has experienced a price change of 2.5%. Over the last three months, the change has been -7.87%. Over the past six months, the figure is -52.42%.

help

Is Cardiff Oncology (CRDF) a profitable company?

Cardiff Oncology (CRDF) has a net income of -$41.44M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of 18.44% indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of -7.7K% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , with a revenue growth rate of 26.42%, providing insight into the company's sales performance and growth. The gross profit is $90K. Operating income is noted at -$45.41M. Furthermore, the EBITDA is -$44.21M.

help

What is the market capitalization of Cardiff Oncology (CRDF)?

Cardiff Oncology (CRDF) has a market capitalization of $118.24M. The average daily trading volume is 450.06K, indicating the stock's liquidity and investor engagement.